News & Events
DOC
Nuremberg, Germany
June 18-21
Club Vit Meeting
Park City, Utah
July 1-4
Masters at the Wave 2009
Maui, Hawaii
July 12-15
European VitreoRetina Society Meeting
Marrakesch, Morocco
September 5-9
Understanding AMD
Learn about the causes of wet AMD and why it's important to understand current treatment options.
NeoVista leadership
An experienced management team, dedicated venture partners — and a growing list of NeoVista accomplishments.
Innovations
NeoVista's proprietary technology makes epiretinal beta radiation therapy a potential addition to wet AMD treatment options.
CABERNET
This important clinical study is now under way; learn more about its design and key endpoints.
Dr. Jackson: Patient experience
Dr. Jackson: Therapy in practice
Dr. de Juan: Efficacy and safety
Dr. de Juan: Beta radiation therapy
Dr. Chong: Anti-VEGF therapies
Mr. Bremridge: AMD challenges
Mr. Bremridge: Wet AMD overview
Dr. Pravin Dugel: PRS Presentation
Dr. Pravin Dugel: Clinical Data Review
NeoVista Surgical Procedure
( 
- Click this icon on the player to view in full screen)
About Wet AMD
NeoVista, Inc., is dedicated to the development of medical technologies that help to advance the treatment of wet age-related macular degeneration (AMD). Wet AMD affects more than 5 million people around the world and is a major cause of blindness in men and women over the age of 50.
The unique technology being developed by NeoVista continues to show promise in clinical studies. It is our goal to help improve the quality of care and reduce the burden of this destructive condition on patients, physicians, and the healthcare system.
Learn more about wet AMD.
Learn more about NeoVista, Inc.
Learn more about epiretinal beta radiation therapy, our innovative core technology.
Learn more about current clinical trials of NeoVista technology.
New Videos
- Visit our new Multimedia page, with video presentations and animated procedures available for viewing.